|
|
|
|
07.15-08.00 |
Meet the Expert 9: Medical management
of Cushing's disease |
| |
|
CLYDE AUDITORIUM |
| |
|
Chair: J Newell Price (Sheffield, UK) |
| |
|
G Chrousos (Athens, Greece) |
| |
|
|
| |
07.15-08.00 |
Meet the Expert 10: Graves' ophthalmopathy |
| |
|
LOMOND AUDITORIUM |
| |
|
Chair: P Perros (Newcastle upon Tyne, UK) |
| |
|
W Wiersinga (Amsterdam, The Netherlands) |
| |
|
|
| |
07.15-08.00 |
Meet the Expert 11: Metabolic, functional
and oncologic consequences of altered GH/IGF expression |
| |
|
HALL 1 |
| |
|
Chair: G Brockman (Berlin, Germany) |
| |
|
P Jenkins (London, UK) |
| |
|
|
| |
07.15-08.00 |
Meet the Expert 12: Growth hormone deficiency
in adults |
| |
|
FORTH ROOM |
| |
|
Chair: D Johnston (London, UK) |
| |
|
E-M Erfurth (Uppsala, Sweden) |
| |
|
|
| |
08.10-10.10 |
Symposium 9: Stromal cell-matrix interactions |
| |
|
LOMOND AUDITORIUM |
| |
|
Chair: G Williams (London, UK) |
S38 |
08.10 |
Role
of heparan sulphates in neuronal stem cell differentiation |
| |
|
J Turnbull (Liverpool, UK) |
S39 |
08.40 |
Hormonal
regulation of mesenchymal stem cell differentiation in bone |
| |
|
F Jakob (Würzburg, Germany) |
S40 |
09.10 |
Cell
adhesion molecules and osteoclast function |
| |
|
M Helfrich (Aberdeen, UK) |
S41 |
09.40 |
Wnt
signalling in the stem cell niche |
| |
|
A Clark (Cardiff, UK) |
| |
|
|
| |
08.10-10.10 |
Symposium 10: Controversies in male health |
| |
|
Generously supported by Ipsen |
| |
|
CLYDE AUDITORIUM |
| |
|
Chair: M Maggi (Florence, Italy) |
S42 |
08.10 |
Does
andropause exist? |
| |
|
A Perheentupa (Turku, Finland) |
S43 |
08.40 |
Cardiovascular
effects of androgens |
| |
|
F Wu (Manchester, UK) |
S44 |
09.10 |
Endocrine
regulation of prostatic growth |
| |
|
Z Culig (Innsbruck, Austria) |
S45 |
09.40 |
Stem
cell therapeutic approaches to male infertility |
| |
|
S Schlatt (Pittsburgh, USA) |
| |
|
|
| |
08.10-10.10 |
Oral Communications 5: Neuroendocrinology
and neoplasia |
| |
|
FORTH ROOM |
| |
|
Chairs: S Tsagarakis (Athens, Greece) & I
Gerendai (Budapest, Hungary) |
OC33 |
08.10 |
Effect
of overexpression of GH secretagogue receptor (GHSR) in the pituitary
of transgenic mice |
| |
|
LM Seoane, D Carmignac, FF Casanueva & ICAF
Robinson |
OC34 |
08.25 |
Transgenic
mice overexpressing urocortin 3 show increased anxiety and depressive
like behaviours but a hyporesponsive ACTH response to stress |
| |
|
P M Jamieson, A Chen & W Vale |
OC35 |
08.40 |
Immunocytochemical
colocalisation of hormones in the human fetal pituitary |
| |
|
ARM Chirculescu, C Badiu, JF Morris & M
Coculescu |
OC36 |
08.55 |
Somatostatin
analogues in the treatment of acromegaly: correlation between somatostatin
receptor subtype expression levels and clinical response |
| |
|
S Petersenn, A Redmann, DK Luedecke & K
Mann |
OC37 |
09.10 |
90Y-dotatate
in the treatment of neuroendocrine tumours |
| |
|
D Handkiewicz-Junak, K Hasse-Lazar, B Jurecka-Lubieniecka,
J Krajewska, J Roskosz, A Kukulska, S Szpak, A Krawczyk & B
Jarzab |
OC38 |
09.25 |
Germline
mutations in patients with apparently sporadic pheochromocytomas/
paragangliomas |
| |
|
M Mannelli, MS Gaglianò, L Simi, T
Ercolino, L Becherini, P Pinzani, R Sestini, GP Bernini, M Mascalchi & M
Genuardi |
OC39 |
09.40 |
11b-hydroxysteroid
dehydrogense modulation of HPA function - importance of genetic
background |
| |
|
RN Carter, U Tworowska, JR Seckl & MC
Holmes |
OC40 |
09.55 |
Expression
of IGF-I and IGF-IR in tamoxifen-sensitive and tamoxifenresistant
breast cancer |
| |
|
CJ McVittie, S Khalaf, W Ogunkolade, R Carpenter,
SA Bustin & PJ Jenkins |
| |
|
|
| |
08.10-10.10 |
Nurses Session: Metabolic syndrome |
| |
|
ALSH ROOM |
| |
|
Chairs: D Greenfield (Sheffield, UK) & S
Shalet (Manchester, UK) |
S97 |
08.10 |
Leptin
expands function |
| |
|
H Randeva (Coventry, UK) |
S98 |
08.35 |
Ghrelin
update |
| |
|
V Popovic (Belgrade, Serbia and Montenegro) |
S99 |
09.00 |
Insulin
resistance and type 2 diabetes - insights from the study of extreme
human phenotypes |
| |
|
D Savage (Cambridge, UK) |
S100 |
09.25 |
Metabolic
syndrome |
| |
|
N Finer (Cambridge, UK) |
S101 |
09.50 |
Nurse-led
weight management: the Counterweight Programme |
| |
|
L McCombie (Glasgow, UK) |
| |
|
|
| |
10.10-10.40 |
COFFEE |
| |
|
HALL 3 |
| |
|
|
| |
10.40-11.25 |
British Thyroid Association Pitt-Rivers
Lecture |
| |
|
CLYDE AUDITORIUM |
| |
|
Chair: A Weetman (Sheffield, UK) |
S5 |
10.40 |
Neurological
abnormalities in mice with a dominant negative thyroid hormone
a1 |
| |
|
B Vennström (Stockholm, Sweden) |
| |
|
|
| |
11.35-12.20 |
Meet the Expert 9: Medical management
of Cushing's disease |
| |
|
CLYDE AUDITORIUM |
| |
|
Chair: J Newell Price (Sheffield, UK) |
| |
|
G Chrousos (Athens, Greece) |
| |
|
|
| |
11.35-12.20 |
Meet the Expert 10: Graves' ophthalmopathy |
| |
|
LOMOND AUDITORIUM |
| |
|
Chair: P Perros (Newcastle upon Tyne, UK) |
| |
|
W Wiersinga (Amsterdam, The Netherlands) |
| |
|
|
| |
11.35-12.20 |
Meet the Expert 11: Metabolic, functional
and oncologic consequences of altered GH/IGF expression |
| |
|
HALL 1 |
| |
|
Chair: G Brockman (Berlin, Germany) |
| |
|
P Jenkins (London, UK) |
| |
|
|
| |
11.35-12.20 |
Meet the Expert 12: Growth hormone deficiency
in adults |
| |
|
FORTH ROOM |
| |
|
Chair: D Johnston (London, UK) |
| |
|
E-M Erfurth (Uppsala, Sweden) |
| |
|
|
| |
12.20-13.50 |
European Society of Endocrinology AGM |
| |
|
CLYDE AUDITORIUM followed by a drinks reception
for attendees in the Gala Foyer |
| |
|
|
| |
13.50-14.50 |
POSTERS AND LUNCH |
| |
|
HALL 3 |
| |
|
|
| |
14.50-16.50 |
Symposium 11: How hormones get into cells |
| |
|
CLYDE AUDITORIUM |
| |
|
Chair: K Chapman (Edinburgh, UK) |
S46 |
14.50 |
Specific
thyroid hormone transporters |
| |
|
T Visser (Rotterdam, The Netherlands) |
S47 |
15.20 |
The
spectrum of MCT8 gene mutations |
| |
|
H Krude (Berlin, Germany) |
S48 |
15.50 |
Multidrug
resistance p-glycoprotein (Mdr-1): excluding corticosteroids from
brain |
| |
|
E de Kloet (Leiden, The Netherlands) |
S49 |
16.20 |
Cell
surface carrier-mediated transport of steroid hormones |
| |
|
J Steffgen (Biberach, Germany) |
| |
|
|
| |
14.50-16.50 |
Symposium 12: Endocrinology in the fetus |
| |
|
HALL 1 |
| |
|
Chair: TBA |
S50 |
14.50 |
Maternal
thyroid function and cognitive impairment in childhood |
| |
|
A van Wassenaer (Amsterdam, The Netherlands) |
S51 |
15.20 |
Molecular
basis of programming of renin-secreting cells |
| |
|
S Pennings (Edinburgh, UK) |
S52 |
15.50 |
Birth
weight and later disease: genes and maternal diabetes |
| |
|
R Lindsay (Glasgow, UK) |
S53 |
16.20 |
Endocrine
therapy of the fetus |
| |
|
A Grüters-Kieslich (Berlin, Germany) |
| |
|
|
| |
14.50-16.50 |
Clinical Management Workshop 4: Contrasting
practices in European endocrinology |
| |
|
LOMOND AUDITORIUM |
| |
|
Chair: B Allolio (Wurzburg, Germany) |
S88/S89 |
14.50 |
Diagnosis of hypercortisolism |
| |
|
R Feelders (Rotterdam, The Netherlands) & A
Atkinson (Belfast, UK) |
S90/S91 |
15.30 |
New endocrinology medicines: S91 when are they
good value? |
| |
|
A Walker (Glasgow, UK) & J Sandahl Christiansen
(Aarhus, Denmark) |
S92/S93 |
16.10 |
Contrasting practices in European S93 endocrinology
- radio-iodine therapy |
| |
|
A Toft (Edinburgh, UK) & L Hegedüs
(Odense, Denmark) |
| |
|
|
| |
14.50-16.50 |
Oral Communications 6: Endocrine genetics |
| |
|
FORTH ROOM |
| |
|
Chairs: K Chatterjee (Cambridge, UK) & W
de Herder (Rotterdam, The Netherlands) |
OC41 |
14.50 |
Mutations
in cullin 7, a cofactor for ubiquitination, cause the 3M intra-uterine
growth retardation syndrome |
| |
|
PE Clayton, L O'Sullivan, A Glaser, MH Oliveira,
MRS de Alacantara, ES de Almeida Barretto, H Kingston, A Read,
V Cormier-Daire, PJ Scambler & G Black |
OC42 |
15.05 |
Linkage
of a fourth gene for familial glucocorticoid deficiency to chromosome
13q |
| |
|
LA Metherell, C Becker, F Ruschendorf, D
Naville, M Begeot, P Nurnberg, A Huebner, MO Savage & AJL Clark |
OC43 |
15.20 |
Mutation
screening of SLC26A4 (PDS) gene in patients with Pendred syndrome
and non-syndromic enlarged vestibular aqueduct |
| |
|
M Ladsous, V Vlaeminck-Guillem, C Vincent,
F Dubrulle, V Dumur & JL Wémeau |
OC44 |
15.35 |
Functional
impact of polymorphic variation in the gene encoding 11b- hydroxylase
(CYP11B1): reduced adrenal 11-hydroxylase efficiency identifies
a key intermediate phenotype in hypertension |
| |
|
M Barr, E Friel, SM MacKenzie, CD Holloway,
EM Freel, NJR Brain, DM Wilkinson, M Ingram, R Fraser, AF Dominiczak,
JMC Connell & E Davies |
OC45 |
15.50 |
Genotype/phenotype
correlation of PRKAR1A mutations in patients with Carney complex
(CNC) and/or sporadic primary pigmented nodular adrenocortical
disease (PPNAD) from the CNC network |
| |
|
L Groussin, F Rene-Corail, L Cazabat, E Jullian,
E Clauser, X Bertagna & J Bertherat |
OC46 |
16.05 |
Predictors
and prevalence of paraganglioma syndrome associated with mutations
of the SDHC-gene |
| |
|
HP Neumann |
OC47 |
16.20 |
Frequent
involvement of BMP15 gene variants in women with premature ovarian
failure |
| |
|
E Di Pasquale, R Rossetti, A Marozzi, S Borgato,
L Cavallo, F de Luca, S Einaudi, G Radetti, G Russo, M Sacco, P
Beck-Peccoz & L Persani |
OC48 |
16.25 |
Progressive
osseous heteroplasia: a phenotype associated with mutations of
the GNAS1 gene |
| |
|
N Richard, G Abeguile & ML Kottler |
| |
|
|
| |
16.50-17.30 |
TEA |
| |
|
HALL 3 |
| |
|
|
| |
17.30-18.15 |
Society for Endocrinology Dale Medal
Lecture |
| |
|
CLYDE AUDITORIUM |
| |
|
Chair: J Wass (Oxford, UK) |
S6 |
17.30 |
The
actions of inhibin in endocrine tissues |
| |
|
J Findlay (Clayton, Australia) |
| |
|
|
| |
From 19.30 |
Congress Banquet and Ceilidh |
| |
|
HILTON HOTEL |
